{
    "Clinical Trial ID": "NCT00847171",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine",
        "  All patients receive weekly Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed adenocarcinoma of the breast, meeting one of the following criteria:",
        "  Metastatic disease",
        "  High-risk disease, defined as early-stage disease with pathologic involvement of locoregional lymph nodes",
        "  Patients who are/will be receiving standard adjuvant trastuzumab [Herceptin\u00ae] for high-risk disease will participate in this study during the single-agent trastuzumab portion of their therapy",
        "  No clinical or radiographical evidence of active disease",
        "  Not eligible for therapy of known curative potential for metastatic breast cancer",
        "  HER2/neu-overexpressing disease, defined as HER2/neu positive by IHC 3+ staining or by FISH+ amplification",
        "  Stable CNS disease allowed provided it has been adequately treated and is not under active treatment",
        "  Hormone receptor status not specified",
        "  PATIENT CHARACTERISTICS:",
        "  Menopausal status not specified",
        "  ECOG performance status 0-1",
        "  ANC > 1,000/mm^3",
        "  Platelet count > 100,000/mm^3",
        "  Serum creatinine < 2.0 mg/dL",
        "  Serum bilirubin  2.0 mg/dL (unless elevation is due to known Gilbert's syndrome)",
        "  AST/ALT  2 times upper limit of normal (ULN)",
        "  Alkaline phosphatase  5 times ULN",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective contraception",
        "  Cardiac ejection fraction normal by MUGA OR  45% by ECHO",
        "  No other malignancies within the past 5 years, except for carcinoma in situ of the cervix, superficial nonmelanoma skin cancer, or superficial bladder cancer",
        "  No prior or currently active autoimmune disease* requiring management with systemic immunosuppression, including any of the following:",
        "  Inflammatory bowel disease",
        "  Systemic vasculitis",
        "  Scleroderma",
        "  Psoriasis",
        "  Multiple sclerosis",
        "  Hemolytic anemia or immune-mediated thrombocytopenia",
        "  Rheumatoid arthritis",
        "  Systemic lupus erythematosus",
        "  Sj\u00f6gren syndrome",
        "  Sarcoidosis",
        "  Other rheumatologic disease",
        "  No symptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at rest",
        "  HIV-negative",
        "  No evidence of active acute or chronic infection",
        "  No uncontrolled medical problems",
        "  No active major medical or psychosocial problems that could be complicated by study participation",
        "  No corn allergy",
        "  No known severe hypersensitivity to trastuzumab (except for mild to moderate infusion reactions that are easily managed and do not recur) NOTE: *Asthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids allowed",
        "  PRIOR CONCURRENT THERAPY:",
        "  Any number of prior chemotherapy regimens for metastatic breast cancer allowed",
        "  Prior or concurrent trastuzumab in the adjuvant or metastatic setting allowed",
        "  More than 28 days since prior and no concurrent systemic oral steroids",
        "  Topical, ocular, or nasal steroids allowed",
        "  More than 28 days since prior and no concurrent chemotherapy, radiotherapy, or biologic therapy (except trastuzumab)",
        "  More than 28 days since prior and no concurrent participation in another investigational clinical trial involving a new drug",
        "  Concurrent endocrine therapy or bisphosphonates allowed"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Safety as Assessed by Number of Participants Experiencing Toxicity",
        "  Safety as assessed by number of participants who experienced drug-related local and systemic toxicity, as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v3.0) in response to CY-modulated immunization with a novel breast cancer vaccine in the setting of weekly Trastuzumab therapy.",
        "  Time frame: 4 years",
        "Results 1: ",
        "  Arm/Group Title: Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine",
        "  Arm/Group Description: All patients receive weekly Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine",
        "  Overall Number of Participants Analyzed: 20",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  Patients with drug-related toxicity: 20 100.0%",
        "  Patients with grade 3+ drug-related toxicity: 0   0.0%",
        "  Patients with serious drug-related toxicity: 0   0.0%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/20 (0.00%)"
    ]
}